Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs

2026-04-05 14:56:25

Abstract generation in progress

Turn Therapeutics has secured up to $25 million in growth capital financing from Avenue Capital Group to advance its clinical programs for atopic dermatitis and onychomycosis, with an immediate $7 million tranche. The funding is expected to extend the company’s financial runway through the mid-year readout of its Phase 2 trial for atopic dermatitis and support preparations for registrational trials of its lead asset, GX-03. Additional funds are contingent on achieving specific clinical and corporate milestones.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.